

Luca Zammataro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477877/publications.pdf>

Version: 2024-02-01

71
papers

3,598
citations

201385

27
h-index

133063

59
g-index

75
all docs

75
docs citations

75
times ranked

6853
citing authors

#	ARTICLE	IF	CITATIONS
1	Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. <i>Nature</i> , 2003, 424, 391-397.	13.7	546
2	The chemokine system in cancer biology and therapy. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 27-39.	3.2	343
3	Differential regulation of iron homeostasis during human macrophage polarized activation. <i>European Journal of Immunology</i> , 2010, 40, 824-835.	1.6	337
4	Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility. <i>Journal of Immunology</i> , 2010, 185, 642-652.	0.4	337
5	Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. <i>Blood</i> , 2012, 119, 411-421.	0.6	292
6	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243.	3.3	181
7	Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. <i>Blood</i> , 2010, 116, 3677-3680.	0.6	163
8	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. <i>Epigenetics</i> , 2011, 6, 95-102.	1.3	74
9	RANK-dependent autosomal recessive osteopetrosis: Characterization of five new cases with novel mutations. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 342-351.	3.1	66
10	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. <i>Breast Cancer Research</i> , 2018, 20, 105.	2.2	58
11	Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis. <i>Frontiers in Immunology</i> , 2014, 5, 128.	2.2	57
12	Type I Collagen Limits VEGFR-2 Signaling by a SHP2 Protein-Tyrosine Phosphatase-Dependent Mechanism. <i>Circulation Research</i> , 2006, 98, 45-54.	2.0	55
13	Polymerase δ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017, 144, 146-152.	0.6	55
14	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 149, 585-591.	0.6	53
15	X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. <i>Clinical and Experimental Immunology</i> , 2012, 169, 253-262.	1.1	52
16	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	3.3	52
17	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. <i>Clinical Cancer Research</i> , 2017, 23, 5836-5845.	3.2	51
18	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	3.3	49

#	ARTICLE	IF	CITATIONS
19	Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48
20	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research, 2018, 24, 3282-3291.	3.2	44
21	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology, 2017, 146, 179-186.	0.6	37
22	Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. Oncotarget, 2016, 7, 35353-35368.	0.8	34
23	Dual-Targeting Nanoparticles for <i>In Vivo</i> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 323-333.	1.9	34
24	Aurora-A kinase oncogenic signaling mediates TGF- β ² -induced triple-negative breast cancer plasticity and chemoresistance. Oncogene, 2021, 40, 2509-2523.	2.6	34
25	The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2 ⁺ and CCR5 ⁺ IFN γ -producing T cells in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L1010-L1025.	1.3	32
26	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget, 2020, 11, 560-570.	0.8	32
27	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports, 2020, 10, 973.	1.6	31
28	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers in Oncology, 2020, 10, 118.	1.3	30
29	A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals of Oncology, 2021, 32, 1045-1046.	0.6	29
30	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology, 2019, 155, 144-150.	0.6	28
31	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer, 2022, 128, 1206-1218.	2.0	28
32	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer, 2016, 115, 303-311.	2.9	27
33	Exome sequencing identifies CTSK mutations in patients originally diagnosed as intermediate osteopetrosis. Bone, 2014, 59, 122-126.	1.4	26
34	<i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Molecular Cancer Therapeutics, 2018, 17, 1003-1011.	1.9	25
35	Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression. Cancers, 2019, 11, 1277.	1.7	24
36	Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors. Journal of Cell Science, 2013, 126, 3181-91.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment. <i>Gynecologic Oncology Reports</i> , 2018, 25, 41-44.	0.3	22
38	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	2.1	20
39	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152.	0.6	18
40	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853.	3.2	18
41	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438.	0.6	18
42	LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer. <i>BMC Bioinformatics</i> , 2016, 17, 80.	1.2	16
43	Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. <i>Medical Oncology</i> , 2017, 34, 91.	1.2	16
44	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. <i>Gynecologic Oncology</i> , 2019, 153, 158-164.	0.6	13
45	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. <i>Gynecologic Oncology</i> , 2021, 163, 334-341.	0.6	10
46	AnnotateGenomicRegions: a web application. <i>BMC Bioinformatics</i> , 2014, 15, S8.	1.2	8
47	Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. <i>Cancer Letters</i> , 2021, 507, 80-88.	3.2	8
48	Involvement of interferon regulatory factor-1 in monocyte CD95 expression and CD95-mediated apoptosis. <i>Cell Death and Differentiation</i> , 2003, 10, 615-617.	5.0	7
49	Continuous Glucose Monitoring Linked to an Artificial Intelligence Risk Index: Early Footprints of Intraventricular Hemorrhage in Preterm Neonates. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 146-153.	2.4	7
50	A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. <i>Cancer Letters</i> , 2021, 496, 84-92.	3.2	7
51	A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH1 methylated characteristics (NCT02899793).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5523-5523.	0.8	5
52	Embryonic cleavage modeling as a computational approach to sphere packing problem. <i>Journal of Theoretical Biology</i> , 2007, 245, 77-82.	0.8	4
53	Large Scale Agent-Based Modeling of the Humoral and Cellular Immune Response. <i>Lecture Notes in Computer Science</i> , 2011, , 15-29.	1.0	3
54	Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 769-775.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188614.	3.3	2
56	Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166313.	1.8	2
57	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14009-e14009.	0.8	1
58	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17028-e17028.	0.8	1
59	Detecting constituent sequences by means of HP pattern-based grammars to synthesize proteins: Inferring sequence-structure-function relationship. , 2007, , .		0
60	Inactive VEGFR2(R1032Q) exerts prooncogenic activity through heterodimerization with wild-type receptor. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
61	Abstract 911: In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. , 2021, , .		0
62	In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, S186-S187.	0.6	0
63	AnnotateGenomicRegions: a web application. <i>EMBnet Journal</i> , 2012, 18, 135.	0.2	0
64	Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors. <i>Development (Cambridge)</i> , 2013, 140, e1607-e1607.	1.2	0
65	Programming Living Machines: The Case Study of Escherichia Coli. <i>Lecture Notes in Computer Science</i> , 2014, , 377-379.	1.0	0
66	Molecular Liaisons between Brain and Cancer: A Hypothesis on the Post-Operative Depression Based on Bioinformatic Evidence. <i>MOJ Proteomics & Bioinformatics</i> , 2015, 2, .	0.1	0
67	Abstract 47: SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. , 2017, , .		0
68	Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma. , 2019, , .		0
69	Abstract C121: Long Pentraxin-3 modulates bladder cancer progression. , 2019, , .		0
70	Abstract 5341: Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. , 2020, , .		0
71	Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma. , 2019, , .		0